Sino Biopharmaceutical (HKG:1177) presented preliminary data from its first-in-human Phase I clinical study of cancer drug TQB2102 at the 2025 ASCO Annual Meeting, according to a Tuesday filing with the Hong Kong Exchange.

The company reported encouraging results, with response rates of up to 70% in certain HER2-positive cancers, including breast and gastric cancers -- even among patients who had not responded to prior treatments.

Side effects were described as manageable, with only a few cases of serious lung-related adverse events.

TQB2102 is currently in Phase 3 trials and, if successful, could become the world's first approved bispecific HER2 antibody-drug conjugate (ADC), the filing said.